ArticleIranian journal of pharmaceutical research : IJPR
Pharmaceutical Utilization Review: A Five-Year Time Trend Analysis of the Pharmaceutical Market in Iran.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: The primary objective of this study was to compare the total and insurance-covered utilization of pharmaceuticals in Iran from March 2018 to March 2023. The findings of this study can offer valuable insights to healthcare professionals, researchers, and policymakers to make informed decisions. Methods: A retrospective cross-sectional study in Iran examined drug utilization patterns (specific databases, e.g., Iranian Health Insurance Organization and Social Security Organization) using Joinpoint regression. The study calculated the Defined Daily Doses per 1000 inhabitants per day (DID) for each medicine based on the anatomical therapeutic chemical/defined daily dose (ATC/DDD) system. All medicines with valid ATC/DDD assignments available during 2018 - 2023 were included to ensure comprehensive national coverage rather than a selected sample. Joinpoint regression was employed for trend analysis, focusing on annual and monthly percent changes in pharmaceutical utilization. Statistical analysis was conducted using MS Excel and Joinpoint software, with significance set at P-value < 0.05. Results: The study assessed 1185 ATC codes, out of which 751 were found eligible for analysis. Among these, 728 were covered by two major Iranian insurance organizations. The study found that the share of insurance utilization of these pharmaceuticals ranged from 27 to 48 percent. The trend utilization showed significant increases in overall utilization in classes C, J, L, N, and P. The utilization trends under insurance coverage revealed that classes L, R, and S showed a significant increase. After the implementation of the Daruyar Plan and the removal of the preferred currency exchange rate for all classes, there has been an increase in utilization under insurance coverage. Conclusions: This study reveals notable patterns and discrepancies in utilization levels within different drug classes, as well as the impact of insurance coverage and the Daruyar Plan on medication utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.